

Press Release

Malmö, SWEDEN – October 3, 2007

Hansa Medical's new share issue totaling SEK 38 M fully subscribed

From September 24 to October 1, 2007, Hansa Medical AB implemented a new share issue comprising 3.8 million shares at an issue price of SEK 10, targeted at the general public. The issue, which generated considerable interest, was fully subscribed and enabled Hansa Medical to raise SEK 38 M before issue expenses. The proceeds of the issue will be used to finance a clinical development plan for Hansa Medical's lead project, IdeS, and key investments in two smaller projects. Following the conclusion of the issue, the total number of shares in Hansa Medical is now 3,924,714 and the company has submitted an application to list its share for trading on First North.

Hansa Medical's CEO, Emanuel Björne:

"We are delighted with the outcome of the new share issue. During 2007, we have established favorable conditions for our lead project, IdeS, to achieve clinical proof-of-concept. The fact that we have now secured financing and are about to implement our development plan is a major success for Hansa Medical. Hansa Medical now faces three exceptionally exciting years, during which we will above all have excellent potential to create an entirely new treatment in conjunction with organ transplantation and convert our sepsis diagnostics into a product."

Through the new share issue, Hansa Medical was spun off from its former owner, Biolin AB (publ), and has now submitted an application to list its share for trading on First North, part of the OMX Nordic Exchange Stockholm. The first day of trading will be October 17, 2007. Hansa Medical's certified advisor is Kaupthing Bank.

As a result of the new share issue, Hansa Medical's share capital has grown from SEK 500,000 to SEK 19,623,570 and the number of shares has increased from 100,000 to 3,924,714. Following the issue, Hansa Medical's Chairman of the Board, Bo Håkansson, owns 36 percent of the shares in Hansa Medical through a holding company. Among other key persons in Hansa Medical, CEO Emanuel Björne, Board member Per Belfrage and research partner Lars Björck subscribed for shares in the new share issue. Biolin's CEO, Fredrik Lindgren, also subscribed for shares. A total of 75 percent of the newly issued shares were subscribed by shareholders in Biolin.

For more information, please contact:

Emanuel Björne, CEO

Telephone: +46 40 630 76 04

Mobile: +46 707 17 54 77

E-mail: emanuel.bjorne@hansamedical.com

Bo Håkansson, Chairman of the Board

Mobile: +46 705 98 57 22

E-mail: bo.hakansson@farstorp.com

ABOUT HANSA MEDICAL

Hansa Medical refines biomedical discoveries into candidate drugs and diagnostic analytical methods. The company's long-term goal is to bring new products to market through collaboration agreements with pharmaceutical and diagnostics companies. Hansa Medical's lead project, IdeS, is an innovative drug for treatment in conjunction with organ transplantation and autoimmune disease. The company also pursues other development projects, including diagnostics and drugs for sepsis.

Hansa Medical AB
CRC Entrance 72
UMAS
SE-205 02 Malmö, Sweden
TELEPHONE +46 40 630 76 04
FAX +46 40 23 93 10

info@hansamedical.com
www.hansamedical.com

VISITING ADDRESS:
Clinical Research Centre at
Malmö University Hospital
Entrance 72
Malmö, Sweden